Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma Plc (RPRX) drives biopharmaceutical innovation by funding therapies through strategic royalty acquisitions. This dedicated news hub provides investors with essential updates on the company's financial developments and industry impact.
Access real-time announcements including quarterly earnings, royalty agreement expansions, and regulatory milestones. Our curated feed helps stakeholders track RPRX's role in advancing treatments across oncology, immunology, and rare diseases.
Discover how Royalty Pharma's unique business model supports drug development while maintaining revenue stability. The page features verified updates on portfolio additions, strategic collaborations, and market analyses relevant to RPRX's position in healthcare finance.
Bookmark this page for streamlined access to Royalty Pharma's official communications and third-party analyses. Check regularly for insights into how the company continues shaping biopharma funding through calculated royalty investments.
Royalty Pharma plc (Nasdaq: RPRX) has announced its dividend for the fourth quarter of 2024. The company's board of directors has approved a dividend payment of $0.21 per Class A ordinary share. This dividend will be distributed on December 10, 2024, to shareholders who are on record as of the close of business on November 15, 2024. The announcement demonstrates Royalty Pharma's commitment to returning value to its shareholders through regular dividend payments.
Royalty Pharma and Ascendis Pharma have entered into a $150 million capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath, the first FDA-approved treatment for hypoparathyroidism in adults. Ascendis will receive an upfront payment of $150 million in exchange for a 3% royalty on U.S. net sales of Yorvipath. The royalty payments will cease upon reaching a multiple of 2.0x, or 1.65x if achieved by December 31, 2029.
This agreement supports Ascendis Pharma's continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch. The transaction reflects the significant value of Yorvipath and Ascendis' commitment to reducing capital costs while maintaining flexibility to support global commercial capabilities.
Royalty Pharma plc (Nasdaq: RPRX) has announced its participation in Morgan Stanley's 22nd Annual Global Healthcare Conference. The company will be featured in a fireside chat on September 5, 2024, at 9:15 a.m. ET. This event presents an opportunity for investors and interested parties to gain insights into Royalty Pharma's operations and strategy.
The presentation will be accessible via webcast from the company's official website, specifically the 'Events' page in the Investors section. For those unable to attend live, the webcast will be archived for a minimum of thirty days, allowing for later viewing. This participation underscores Royalty Pharma's commitment to engaging with the investment community and sharing its perspective on the healthcare sector.
Royalty Pharma (Nasdaq: RPRX) reported strong financial results for Q2 2024, showcasing a 12% growth in Portfolio Receipts to $608 million and 11% growth in Royalty Receipts to $605 million. The company raised its 2024 full-year guidance for Portfolio Receipts to $2,700-$2,775 million. Highlighting their capital deployment of over $2 billion, investments spanned six therapies, including notable partnerships with Cytokinetics, PTC Therapeutics, and Agios. Significant clinical updates featured positive Phase 3 results for Tremfya and FDA approval of Voranigo. Additionally, Royalty Pharma repurchased Class A ordinary shares worth $115 million YTD and maintained robust liquidity with $1.8 billion in cash and $7.8 billion in debt.
Royalty Pharma (Nasdaq: RPRX) has appointed Molly Sawaya as Executive Vice President, Head of Human Capital. Sawaya joins from Hudson Bay Capital, where she was Managing Director and Head of Colleague Experience. She brings nearly 15 years of HR experience from global organizations, including QBE Insurance Group, Perpetual , and National Australia Bank.
Sawaya holds a Bachelor of Arts and Master of Applied Science in Psychology from the University of Sydney. CEO Pablo Legorreta emphasized her role in fostering a thriving work environment and supporting the company's growth as it continues to scale. This appointment aims to strengthen Royalty Pharma's leadership team and cultivate its unique culture.
Royalty Pharma plc (Nasdaq: RPRX) has announced that it will release its second quarter 2024 financial results on Thursday, August 8, 2024, before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time on the same day to discuss the results.
Investors can access the conference call information and view the live webcast on the 'Investors' page of Royalty Pharma's website. A replay of the conference call and webcast will be available on the company's website for at least 30 days after the event.
Royalty Pharma plc (Nasdaq: RPRX) has announced its dividend for the third quarter of 2024. The company's board of directors has approved a payment of $0.21 per Class A ordinary share. This dividend will be distributed on September 13, 2024, to shareholders who are on record as of the close of business on August 16, 2024. This announcement provides investors with information about the company's ongoing commitment to returning value to shareholders through regular dividend payments.
Royalty Pharma (Nasdaq: RPRX) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. The company will engage in a fireside chat scheduled for 2:00 p.m. ET. The event will be webcast live and later archived for at least thirty days, accessible through Royalty Pharma's Events page.
Royalty Pharma (Nasdaq: RPRX) announced the pricing of $1.5 billion in senior unsecured notes.
The offering includes $500 million of 5.150% Notes due 2029, $500 million of 5.400% Notes due 2034, and $500 million of 5.900% Notes due 2054. These notes will be guaranteed by Royalty Pharma Holdings.
The transaction is expected to close on June 10, 2024. Proceeds will be used for general corporate purposes.
Major financial institutions such as BofA Securities, Citigroup, and J.P. Morgan are among the joint lead book-running managers.
Royalty Pharma announced a $905 million agreement with Agios Pharmaceuticals to acquire future royalties on Servier’s vorasidenib, contingent on FDA approval. Vorasidenib, a targeted therapy for IDH-mutant glioma, has shown unprecedented efficacy and tolerability in Phase 3 trials and received priority review with a PDUFA date of August 20, 2024.
The drug is projected to achieve over $1 billion in annual peak sales in the U.S., potentially generating more than $150 million in annual royalties for Royalty Pharma. If approved, royalties may continue through 2038.
An investor call is scheduled for today, May 28, to discuss the deal.